IP Library Granted Patent US 9,644,184
Granted Patent B2
US 9,644,184 · App. 13/794,297 · Granted May 9, 2017

Methods for the production of IPS cells using Epstein-Barr (EBV)-based reprogramming vectors

Inventor: Amanda Mack (Madison, WI)
Assignee: Cellular Dynamics International, Inc.
C12N5/0696C07K14/005C12N15/85C12N2501/602C12N2501/603C12N2501/604C12N2501/605C12N2501/606C12N2501/608C12N2510/00C12N2710/16222C12N2800/107C12N2800/108C12N2800/24C12N2820/60C12N2840/105C12N2840/206
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,644,184
App. No.
13/794,297
Granted
May 9, 2017
Kind
B2
Abstract

Methods and composition of induction of pluripotent stem cells and other desired cell types are disclosed. For example, in certain aspects methods for generating essentially vector-free induced pluripotent stem cells are described. Furthermore, the invention provides induced pluripotent stem cells and desired cell types essentially free of exogenous vector elements with the episomal expression vectors to express differentiation programming factors.

Claims (10)

1. An isolated population of human induced pluripotent stem (iPS) cells, said population comprising human pluripotent cells that comprise Epstein-Barr virus (EBV)-based reprogramming vectors comprising a replication origin and one or more expression cassettes encoding iPS reprogramming factors comprising at least Sox-2, Oct-4, wherein said cells, or one or more of said expression cassettes, comprise a nucleotide sequence encoding a trans-acting factor that binds to the replication origin to replicate an extra-chromosomal template, the cell population comprising the genome of a selected adult human individual and essentially free of chromosomally integrated retroviral elemants.

2. The isolated human iPS cell population of claim 1 , wherein the genome is that of a terminally differentiated human cell.

3. The isolated population of claim 1 , wherein the Epstein-Barr virus (EBV)-based vectors encode at least the reprogramming factors Oct4 and Sox2, and additionally one or more of the reprogramming factors selected from the group consisting of Lin28, Nanog, Klf4 and c-Myc.

4. The isolated population of claim 1 , wherein the population further comprises human pluripotent cells that are essentially free of Epstein-Barr (EBV)-based vectors.

5. An isolated population of human induced pluripotent stem (iPS) cells, said population comprising human pluripotent cells that comprise Epstein-Barr virus (EBV)-based reprogramming vectors comprising a replication origin and one or more expression cassettes encoding at least the reprogramming factors Oct4 and Sox2, and additionally one or more of the reprogramming factors selected from the group consisting of Lin28, Nanog, Klf4 and c-Myc, wherein said cells, or one or more of said expression cassettes, comprise a nucleotide sequence encoding a trans-acting factor that binds to the replication origin to replicate an extra-chromosomal template, wherein the iPS cells of the population have been produced from somatic cells of a selected human individual and comprise the genome of that individual and are essentially free of chromosomally integrated retroviral elements.

6. The isolated population of claim 5 , wherein the population further comprises human pluripotent cells that are essentially free of Epstein-Barr (EBV)-based vectors.

7. The isolated population of claim 4 or 6 , wherein the human pluripotent cells that comprise Epstein-Barr (EBV)-based vectors constitute less than 10% of said population.

8. The isolated population of claim 7 , wherein the human pluripotent cells that comprise Epstein-Barr (EBV)-based vectors constitute less than 1% of said population.

9. The isolated population of claim 8 , wherein the human pluripotent cells that comprise Epstein-Barr (EBV)-based vectors constitute less than 0.5% of said population.

10. The isolated population of claim 9 , wherein the human pluripotent cells that comprise Epstein-Barr (EBV)-based vectors constitute less than 0.1% of said population.

Assignments (1)
CHANGE OF NAME Recorded May 3, 2018
From: CELLULAR DYNAMICS INTERNATIONAL, INC.
To: FUJIFILM CELLULAR DYNAMICS, INC.
Reel/Frame 046069/0525 →
Continuity (4)
Division 12478154 · Jun 4, 2009
Provisional Application 61160584 · Mar 16, 2009
Provisional Application 61058858 · Jun 4, 2008
Related Publication 20130189778A1 · Jul 25, 2013